The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Mogamulizumab for patients with CTCL
Mogamulizumab is a monoclonal antibody that induces antibody-dependent cell-mediated toxicity (ADCC) upon binding to both the transmembrane chemokine receptor CCR4, which is upregulated on malignant CTCL cells, and natural killer (NK) cells. Samuel Wilding, University of Manchester, Manchester, UK, presents data from a Phase II study (NCT04745234) evaluating the efficacy and the safety of mogamulizumab in patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) including Sézary syndrome (SS) and mycosis fungoides (MF). This study reported improvements in skin and hematological response, with low rates of adverse events, resulting in an overall improvement of these patients’ quality of life (QoL). This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
